ArticleBlood2019

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Joseph Mikhael et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.